DOI · e01.org

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)

Mi Hwa Heo, Hee Kyung Kim, Hansang Lee, Kyoung‐Mee Kim, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park, Seung Tae Kim · Journal of Cancer · 2017

  • DOI 10.7150/jca.17898
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2017

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2017

Abstract

Background: c-MET is a proto-oncogene that encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF).Activation of HGF-c-MET signaling involves cell invasiveness and evokes metastasis through direct involvement of tumor angiogenesis.However, the value of c-MET overexpression is still unknown in metastatic biliary tract cancer (BTC).Methods: We analyzed the incidence and clinicopathologic characteristics of c-MET overexpression in advanced BTC.Moreover, we investigated the value of c-MET overexpression in predicting response to gemicitabine plus cisplatin (GC), a first line standard regimen, and as a prognostic marker in metastatic BTC.

Results:The BTC subtype distribution (N=44) was as follows: intrahepatic cholangiocarcinoma (IHCC, n=7), extrahepatic cholangiocarcinoma (EHCC, n=25) and gallbladder cancer (GBC, n=12).Liver (52.3%) was the predominant metastatic site, followed by lymph nodes (36.4%) and bone (15.9%).Among the 44 patients analyzed for c-MET expression, 15 (34.1%) exhibited c-MET overexpression in tumor tissues.There was no significant difference in the prevalence of c-MET overexpression among primary sites in EHCC (7/25, 28.0%), IHCC (3/7, 42.9%), and GBC (5/12, 41.7%).There was also no significant correlation between specific clinicopathologic variables and c-MET expression.Comparing the tumor-response to GC according to c-MET expression (overexpression vs. non-overexpression), there was no significant difference in either RR or DCR (p=0.394 and p >0.999, respectively).The median PFS for all 44 patients was 9.00 months (95% CI, 7.5-10.5 months) and there was no significant difference for PFS between patients with c-MET overexpression and those without (p=0.917).The median OS was 14.4 months (95% CI, 11.9-16.9months).There was no significant difference in OS between patients with c-MET overexpression compared to those without (13.7 vs.

14.4 months, respectively; p=0.708).Conclusions: c-MET overexpression was detected in 34.1% of advanced BTC patients irrespective of tumor location.c-MET overexpression did not predict response to GC or survival.Further studies are needed to fully elucidate the value of c-MET overexpression as a novel biomarker in these patients.

Open the resolved locator · 10.7150/jca.17898

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:12 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v08p1395.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.